Patents Examined by Andre Mach
  • Patent number: 12343472
    Abstract: An object of the present invention is to provide a powder preparation and the like suitable for selective administration to an olfactory region and the like. The object is achieved by a powder preparation for selectively administering an active ingredient to an olfactory region in a nasal cavity, the powder preparation comprising the active ingredient and having a bulk density of 0.1 to 0.5 g/cm3 and a Hausner ratio of 1.6 to 2.4.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: July 1, 2025
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventor: Shunji Haruta
  • Patent number: 12290608
    Abstract: The present disclosure provides wound dressing compositions that disrupt biofilm formation in a wound upon application. The wound dressing composition includes a first layer comprising a homogeneous mixture of a collagen, an oxidized regenerated cellulose (ORC), and at least one bacteria reducing active ingredient and a second layer comprising a homogeneous mixture of a collagen, an oxidized regenerated cellulose (ORC), a silver compound, and at least one bacteria reducing active ingredient, and the uses thereof. Also disclosed herein are kits comprising the wound dressing compositions of the present technology, and instructions for use.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: May 6, 2025
    Assignee: Solventum Intellectual Properties Company
    Inventors: Kathleen L. Derrick, Kristine M. Kieswetter
  • Patent number: 12285524
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one liposome and an antipsychotic drug with a high drug to lipid ratio and encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the antipsychotic drug. Also provided is the method for treating schizophrenia or bipolar disorder using the pharmaceutical composition disclosed herein.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: April 29, 2025
    Assignees: TAIWAN LIPOSOME CO., LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Keelung Hong, Jonathan Fang, Hao-Wen Kao, Yi-Yu Lin, Walter Gwathney
  • Patent number: 12285012
    Abstract: Disclosed herein are compositions comprising (a) a pyridine carboxylate herbicide or an agriculturally acceptable N-oxide, salt, or ester thereof and (b) an acetolactate synthase (ALS) inhibitor or an agriculturally acceptable salt or ester thereof. Also disclosed herein are methods of controlling undesirable vegetation, comprising applying to vegetation or an area adjacent the vegetation or applying in soil or water to control the emergence or growth of vegetation (a) a pyridine carboxylate herbicide or an agriculturally acceptable N-oxide, salt, or ester thereof and (b) an ALS inhibitor or an agriculturally acceptable salt or ester thereof.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: April 29, 2025
    Assignee: CORTEVA AGRISCIENCE LLC
    Inventors: Jeremy Kister, Norbert M. Satchivi
  • Patent number: 12274770
    Abstract: This invention relates to stabilizer concentrates which improve the stability of mono- and/or diesters of mono- and/or diethylene glycol wax dispersions in personal care compositions, wherein the stabilizer concentrates comprising hydrogenated castor oil and betaines and are free of anionic surfactants.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: April 15, 2025
    Assignee: BASF SE
    Inventors: Claus Nieendick, Werner Mauer, Kathrin Tapp, Sybille Cornelsen
  • Patent number: 12268740
    Abstract: The present invention relates to filamentous, i.e. thread-like nanoparticles comprising sterol and a component derived from Quillaja saponaria Molina selected from quillaja acid and quillaja saponin. More particularly, the invention relates to the use of said thread-like nanoparticles in vaccines and drug delivery or adsorption systems systems, methods for their production and uses thereof, such as for use as a vaccine adjuvant and in cancer therapy.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: April 8, 2025
    Assignee: Croda International Plc
    Inventors: Kefei Hu, Laurent Duroux, Erik Lindblad
  • Patent number: 12233131
    Abstract: Technical field The invention relates to new calibrated-size gas-filled microvesicles bearing an overall positive charge, to their use and to their method of manufacturing. The gas-filled microvesicles have a geometric standard deviation (GSD) value of at least 1.25 or lower and a stabilizing envelope comprising an amphiphilic material, said amphiphilic material comprising a cationic lipid and a neutral or cationic amphiphilic polymeric compound.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: February 25, 2025
    Assignee: Bracco Suisse SA
    Inventors: Anne Lassus, Samir Cherkaoui
  • Patent number: 12171746
    Abstract: A liposome composition comprising a lipophilic prodrug of mitomycin C having an improved pharmacokinetic profile is described. A method for preparing the composition with a solvent system comprised of ethanol and tertiary butanol mixed at an adequate ratio is also described. In an embodiment, the liposome composition is a population of lipid nanoparticles and a pharmaceutically acceptable vehicle, wherein the population of lipid nanoparticles is comprised of a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the second fraction is less than about 15% of the population of lipid nanoparticles.
    Type: Grant
    Filed: January 11, 2020
    Date of Patent: December 24, 2024
    Assignees: Lipomedix Pharmaceuticals Ltd., Sharre Zedek Scientific Ltd.
    Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
  • Patent number: 12161664
    Abstract: Provided is a method, and pharmaceutical composition, to treat or prevent cyanide poisoning and/or methylmercaptan poisoning comprising administering to a subject in need an effective amount of tetrathionate by intramuscular injection or by intranasal administration. Also provided is a method for detecting the presence of tetrathionate in a sample by reacting it with cyanide and measuring the resulting thiocyanate with ferric nitrate.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: December 10, 2024
    Assignees: The Regents of the University of California, The Regents of the University of Colorado
    Inventors: Gerry R. Boss, Adriano Chan, Matthew Brenner, Sari Brenner Mahon, Vikhyat Bebarta
  • Patent number: 12083226
    Abstract: An object of the present invention is to provide a solid drug formulation having excellent stability. The solution according to the present invention is a solid drug formulation containing: a compound having formula (I): (i) D-mannitol; (ii) carmellose calcium; (iii) citric acid hydrate or the like; and (iv) ?-tocopherol.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: September 10, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroaki Arai, Shinji Yoshinaga, Yurika Ozaki
  • Patent number: 11992554
    Abstract: A polyfunctional radical scavenger hydrogel formulation providing extended protection of the extracellular space within a wound site. The polyfunctional radical scavenger hydrogel formulation is generally formed from a hydrogel, a first radical scavenger and a second radical scavenger differing from the first radical scavenger with respect to at least one property. A portion of the first radical scavenger included with the formation and/or second radical scavenger included within the formulation may be dissolved, suspended and/or bonded to a polymer of the hydrogel.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: May 28, 2024
    Assignee: RXOS MEDICAL, INC.
    Inventors: Richard M. Millis, Jeffrey A. Niezgoda, Rajagopalan Sridhar
  • Patent number: 11992558
    Abstract: The present invention relates to a controlled release oral formulation comprising about 400 mg to about 800 mg of flavoxate salt as an active ingredient, suitable polymers, binders, and excipients, and lacking an acidifying agent. The present invention also provides a method of preparing the controlled release oral formulation of about 400 mg to 800 mg of flavoxate salt. The controlled release formulation of present invention may comprise micronized particles of drug. The controlled release formulation has a controlled release profile of up to 24 hours, that is pH independent, and that is alcohol dose dumping risk-free.
    Type: Grant
    Filed: July 21, 2019
    Date of Patent: May 28, 2024
    Inventor: Sushma Paul Berlia
  • Patent number: 11904021
    Abstract: The subject invention pertains to compositions and methods for making and use of metal-based coated nanoparticles. The metal-based, PEG-coated nanoparticles of the invention comprise folic acid molecules on their surface exercise dual functionality by specifically targeting renal tubule cells and treating renal fibrosis.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: February 20, 2024
    Assignee: THE CHINESE UNIVERSITY OF HONG KONG
    Inventors: Chung Hang Jonathan Choi, Cecilia Ka Wing Chan, Yun Wong James Lau
  • Patent number: 11890291
    Abstract: Nanogel and nanoparticles comprising vitamin D encapsulated in agar-agar and a polymer selected from poly(acrylamidoglycolic acid) and pectin are provided. Also provided is aqueous nanogel compositions which can be used for prevention or treatment of vitamin D deficiency and methods for encapsulating vitamin D in nanogels and nanoparticles. The nanogel and nanoparticles and compositions thereof are cost-effective, have a considerable shelf life, a faster rate of absorption in the body leading to faster bioavailability. Further, the nanogels and nanoparticles are made with vegetarian sources and causes no changes in the organoleptic properties. The Vitamin D nanogels and nanoparticles developed can be used for fortification of any food, aqueous medium or beverage, including bottled drinking water.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: February 6, 2024
    Assignee: INNOVA AGRI BIO PARK PRIVATE LIMITED
    Inventors: Krishna Murthy Ella, Kankanallu Shankaranarayana Ravi
  • Patent number: 11878031
    Abstract: The oral administration of bioavailable silicic acid, such as choline-stabilized silicic acid during a period of at least 3 months daily leads to the prevention, inhibition and or treatment of periodontitis and peri-implantatis. The treatment is particularly suitable in combination with appropriate cleaning of the teeth and disinfecting the mouth, by one or more antiseptic and/or antimicrobial agent(s), as carried out at least once and suitably regularly, such as once per year, twice per year, four times per year or even every second month or every month. The treatment may be further enhanced by simultaneous administration of vitamins, trace elements, as well as by administration of a probioticum. Such additional agents may be applied separately, but are preferably incorporated in the formulation of bioavailable silicic acid.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: January 23, 2024
    Assignee: Bio Minerals N.V.
    Inventors: Mario Remi Yvonne Calomme, Kathleen Jozef Ingrid Suzanne Van Hoof
  • Patent number: 11865158
    Abstract: The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D3, coated with zwitterionic chitosan (ZWC) and polymyxin B (PMB). The invention described herein also pertains to pharmaceutical compositions and methods for the treatment of sepsis.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: January 9, 2024
    Assignee: Purdue Research Foundation
    Inventors: Yoon Yeo, Simseok Yuk
  • Patent number: 11825845
    Abstract: The present invention provides materials and methods of making materials, where at least one surface of the material utilizes an emulsion to controllably release active agents, which can include hydrophilic agents, into the surrounding environment. Preferably, the materials are ‘slippery’ in that liquid droplets and other compounds, such as aqueous fluids, organic compounds and microorganisms, are able to easily slide off the surface without adhering to the surface. The active agents released by the emulsion may include antimicrobial agents, antifungal agents, antibacterial agents and other molecules that can kill or otherwise reduce the number of the pathogens. The resulting materials have improved anti-fouling behaviors compared to many other existing types of anti-fouling surfaces.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: November 28, 2023
    Inventors: David M. Lynn, Harshit Agarwal